109 related articles for article (PubMed ID: 23793880)
1. Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms.
Rotunno G; Guglielmelli P; Biamonte F; Rumi E; Cazzola M; Vannucchi AM
Ann Hematol; 2014 Mar; 93(3):523-4. PubMed ID: 23793880
[No Abstract] [Full Text] [Related]
2. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN.
Thoennissen NH; Lasho T; Thoennissen GB; Ogawa S; Tefferi A; Koeffler HP
Am J Hematol; 2011 Aug; 86(8):703-5. PubMed ID: 21674579
[No Abstract] [Full Text] [Related]
3. DNMT3A mutations in myeloproliferative neoplasms.
Stegelmann F; Bullinger L; Schlenk RF; Paschka P; Griesshammer M; Blersch C; Kuhn S; Schauer S; Döhner H; Döhner K
Leukemia; 2011 Jul; 25(7):1217-9. PubMed ID: 21537334
[No Abstract] [Full Text] [Related]
4. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
5. p53 lesions in leukemic transformation.
Harutyunyan A; Klampfl T; Cazzola M; Kralovics R
N Engl J Med; 2011 Feb; 364(5):488-90. PubMed ID: 21288114
[No Abstract] [Full Text] [Related]
6. [A case of atypical myeloproliferative disorder transformed to acute myeloid leukemia with monosomy 7].
Takai K; Sanada M; Honma K
Rinsho Ketsueki; 1988 Feb; 29(2):221-6. PubMed ID: 3164423
[No Abstract] [Full Text] [Related]
7. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.
Andrikovics H; Nahajevszky S; Koszarska M; Meggyesi N; Bors A; Halm G; Lueff S; Lovas N; Matrai Z; Csomor J; Rasonyi R; Egyed M; Varkonyi J; Mikala G; Sipos A; Kozma A; Adam E; Fekete S; Masszi T; Tordai A
Leukemia; 2010 Oct; 24(10):1809-13. PubMed ID: 20811399
[No Abstract] [Full Text] [Related]
8. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
Tefferi A
Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
[No Abstract] [Full Text] [Related]
9. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.
Schneider F; Bohlander SK; Schneider S; Papadaki C; Kakadyia P; Dufour A; Vempati S; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Wandt H; Hiddemann W; Spiekermann K
Leukemia; 2007 Oct; 21(10):2199-201. PubMed ID: 17625612
[No Abstract] [Full Text] [Related]
10. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
11. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
Li B; Mascarenhas JO; Rampal RK
Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
[TBL] [Abstract][Full Text] [Related]
12. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.
Abdel-Wahab O; Pardanani A; Patel J; Wadleigh M; Lasho T; Heguy A; Beran M; Gilliland DG; Levine RL; Tefferi A
Leukemia; 2011 Jul; 25(7):1200-2. PubMed ID: 21455215
[No Abstract] [Full Text] [Related]
13. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
Rampal R; Mascarenhas J
Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
[TBL] [Abstract][Full Text] [Related]
15. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
16. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.
Makishima H; Jankowska AM; Tiu RV; Szpurka H; Sugimoto Y; Hu Z; Saunthararajah Y; Guinta K; Keddache MA; Putnam P; Sekeres MA; Moliterno AR; List AF; McDevitt MA; Maciejewski JP
Leukemia; 2010 Oct; 24(10):1799-804. PubMed ID: 20724984
[No Abstract] [Full Text] [Related]
17. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in members of the Wnt pathway in acute leukemia.
Erbilgin Y; Ng OH; Mavi N; Ozbek U; Sayitoglu M
Leuk Lymphoma; 2012 Mar; 53(3):508-10. PubMed ID: 21902576
[No Abstract] [Full Text] [Related]
19. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?
Tefferi A
Leukemia; 2011 Jul; 25(7):1059-63. PubMed ID: 21750560
[No Abstract] [Full Text] [Related]
20. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies.
Kirito K; Sakoe K; Shinoda D; Takiyama Y; Kaushansky K; Komatsu N
Haematologica; 2008 Jan; 93(1):155-6. PubMed ID: 18166807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
